Genzyme Jumps First Consent Decree Hurdle
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme - out to assure investors and hostile bidder Sanofi that its business is back on track - says it successfully met the first requirement of an FDA consent decree.
You may also be interested in...
Sanofi Claims Genzyme With $20.1 Billion Upfront And CVRs
Sanofi-Aventis SA's drawn out and much-publicized semi-battle to acquire Genzyme Corp. for $20.1 billion, or $74 per share, plus potential future payments, ended on Feb. 16, in a deal that most of those involved as well as many onlookers said was an expensive, albeit strategic, win-win.
Sanofi Claims Genzyme With $20.1 Billion Upfront And CVRs
Sanofi-Aventis SA's drawn out and much-publicized semi-battle to acquire Genzyme Corp. for $20.1 billion, or $74 per share, plus potential future payments, ended on Feb. 16, in a deal that most of those involved as well as many onlookers said was an expensive, albeit strategic, win-win.
Fabrazyme Patients Ask FDA To Retool Genzyme's Product Distribution Plan
If the agency stops Genzyme from exporting its Fabry disease treatment Fabrazyme (agalsidase beta), there will be enough for U.S. patients, a citizen petition says.